{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:26:27Z","timestamp":1789388787366,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the introduction of novel targeted therapies, chemotherapy still remains the primary treatment for metastatic melanoma in poorly funded healthcare environments or in case of disease relapse, with no reliable molecular markers for progression-free survival (PFS) available. As chemotherapy primarily eliminates cancer cells by apoptosis, we here evaluated if the expression of key apoptosis regulators (Bax, Bak, Bcl-2, Bcl-xL, Smac, Procaspase-9, Apaf-1, Procaspase-3 and XIAP) allows prognosticating PFS in stage III\/IV melanoma patients. Following antibody validation, marker expression was determined by automated and manual scoring of immunohistochemically stained tissue microarrays (TMAs) constructed from treatment-naive metastatic melanoma biopsies. Interestingly and counter-intuitively, low expression of the pro-apoptotic proteins Bax, Bak and Smac indicated better prognosis (log-rank p\u2009&lt;\u20090.0001, p\u2009=\u20090.0301 and p\u2009=\u20090.0227 for automated and p\u2009=\u20090.0422, p\u2009=\u20090.0410 and p\u2009=\u20090.0073 for manual scoring). These findings were independently validated in the cancer genome atlas (TCGA) metastatic melanoma cohort (TCGA-SKCM) at transcript level (log-rank p\u2009=\u20090.0004, p\u2009=\u20090.0104 and p\u2009=\u20090.0377). Taking expression heterogeneity between the markers in individual tumour samples into account allowed defining combinatorial Bax, Bak, Smac signatures that were associated with significantly increased PFS (p\u2009=\u20090.0002 and p\u2009=\u20090.0028 at protein and transcript level, respectively). Furthermore, combined low expression of Bax, Bak and Smac allowed predicting prolonged PFS (&gt;\u200912 months) on a case-by-case basis (area under the receiver operating characteristic curve (ROC AUC)\u2009=\u20090.79). Taken together, our results therefore suggest that Bax, Bak and Smac jointly define a signature with potential clinical utility in chemotherapy-treated metastatic melanoma.<\/jats:p>","DOI":"10.1038\/s41419-020-2309-3","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:03:00Z","timestamp":1581591780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Cristiano","family":"Gutt\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Aura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dynoodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie M.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Hirschenhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesuchristopher","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7129-2990","authenticated-orcid":false,"given":"Jasper","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"de Chaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairin","family":"Rafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.","family":"van den Oord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-9261","authenticated-orcid":false,"given":"Markus","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"2309_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1159\/000448904","volume":"39","author":"MV Heppt","year":"2016","unstructured":"Heppt, M. V. et al. The systemic management of advanced melanoma in 2016. Oncol. Res. Treat. 39, 635\u2013642 (2016).","journal-title":"Oncol. Res. Treat."},{"key":"2309_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-016-0421-5","volume":"17","author":"K Margolin","year":"2016","unstructured":"Margolin, K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr. Treat. Options Oncol. 17, 1\u201314 (2016).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2309_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues, B., Lopes, J., Soares, P. & Populo, H. Melanoma treatment in review. ImmunoTargets Ther. 7, 35\u201349 (2018).","journal-title":"ImmunoTargets Ther."},{"key":"2309_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","volume":"33","author":"P Lui","year":"2007","unstructured":"Lui, P. et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat. Rev. 33, 665\u2013680 (2007).","journal-title":"Cancer Treat. Rev."},{"key":"2309_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/mmt-2017-0003","volume":"4","author":"A Gupta","year":"2017","unstructured":"Gupta, A., Gomes, F. & Lorigan, P. The role for chemotherapy in the modern management of melanoma. Melanoma Manag 4, 125\u2013136 (2017).","journal-title":"Melanoma Manag"},{"key":"2309_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton, M. R. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18, 158\u2013158 (2000).","journal-title":"J. Clin. Oncol."},{"key":"2309_CR7","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","volume":"24","author":"AY Bedikian","year":"2006","unstructured":"Bedikian, A. Y. et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J. Clin. Oncol. 24, 4738\u20134745 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2309_CR8","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"MB Atkins","year":"2008","unstructured":"Atkins, M. B. et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (e3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 26, 5748\u20135754 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2309_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2012.161","volume":"3","author":"RA Anvekar","year":"2012","unstructured":"Anvekar, R. A. et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis. 3, 1\u201311 (2012).","journal-title":"Cell Death Dis."},{"key":"2309_CR10","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/carcin\/bgm188","volume":"28","author":"M Sanada","year":"2007","unstructured":"Sanada, M. et al. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis 28, 2657\u20132663 (2007).","journal-title":"Carcinogenesis"},{"key":"2309_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49\u201363 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2309_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrm2952","volume":"11","author":"SWG Tait","year":"2010","unstructured":"Tait, S. W. G. & Green, D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11, 621\u2013632 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2309_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/156652411794474400","volume":"11","author":"CT Hellwig","year":"2011","unstructured":"Hellwig, C. T., Passante, E. & Rehm, M. The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. Curr. Mol. Med. 11, 31\u201347 (2011).","journal-title":"Curr. Mol. Med."},{"key":"2309_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2309_CR15","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas, M. S. & Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138\u20133151 (2003).","journal-title":"Oncogene"},{"key":"2309_CR16","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2004.11.070","volume":"22","author":"DC Lev","year":"2004","unstructured":"Lev, D. C. et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J. Clin. Oncol. 22, 2092\u20132100 (2004).","journal-title":"J. Clin. Oncol."},{"key":"2309_CR17","doi-asserted-by":"publisher","DOI":"10.4161\/23723548.2014.964037","volume":"1","author":"EM Charles","year":"2014","unstructured":"Charles, E. M. & Rehm, M. Key regulators of apoptosis execution as biomarker candidates in melanoma. Mol. Cell Oncol. 1, e964037 (2014).","journal-title":"Mol. Cell Oncol."},{"key":"2309_CR18","first-page":"1","volume":"1","author":"RA Anvekar","year":"2011","unstructured":"Anvekar, R. A., Asciolla, J. J., Missert, D. J. & Chipuk, J. E. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival. Apoptosis Treat. Front. Oncol. 1, 1\u201316 (2011).","journal-title":"Apoptosis Treat. Front. Oncol."},{"key":"2309_CR19","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-04-0046","volume":"64","author":"JM Cummins","year":"2004","unstructured":"Cummins, J. M. et al. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64, 3006\u20133008 (2004).","journal-title":"Cancer Res."},{"key":"2309_CR20","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1038\/sj.onc.1210985","volume":"27","author":"P Geserick","year":"2008","unstructured":"Geserick, P. et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27, 3211\u20133220 (2008).","journal-title":"Oncogene"},{"key":"2309_CR21","doi-asserted-by":"publisher","first-page":"16897","DOI":"10.1073\/pnas.0403405101","volume":"101","author":"M Kohli","year":"2004","unstructured":"Kohli, M. et al. SMAC\/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc. Natl Acad. Sci. USA 101, 16897\u201316902 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2309_CR22","doi-asserted-by":"publisher","first-page":"29652","DOI":"10.1074\/jbc.M603487200","volume":"281","author":"AK Samraj","year":"2006","unstructured":"Samraj, A. K., Keil, E., Ueffing, N., Schulze-Osthoff, K. & Schmitz, I. Loss of caspase-9 provides genetic evidence for the type I\/II concept of CD95-mediated apoptosis. J. Biol. Chem. 281, 29652\u201329659 (2006).","journal-title":"J. Biol. Chem."},{"key":"2309_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35051606","volume":"409","author":"MS Soengas","year":"2001","unstructured":"Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207\u2013211 (2001).","journal-title":"Nature"},{"key":"2309_CR24","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1038\/onc.2011.497","volume":"31","author":"C Wang","year":"2012","unstructured":"Wang, C. & Youle, R. J. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1\u2019s inhibitory effect on Bak. Oncogene 31, 3177\u20133189 (2012).","journal-title":"Oncogene"},{"key":"2309_CR25","unstructured":"UCSC Xena. Available at: https:\/\/xena.ucsc.edu\/. (Accessed 24 Oct 2018)."},{"key":"2309_CR26","doi-asserted-by":"publisher","unstructured":"Goldman, M. et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. bioRxiv 326470 (2019). https:\/\/doi.org\/10.1101\/326470.","DOI":"10.1101\/326470"},{"key":"2309_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416.e11 (2018).","journal-title":"Cell"},{"key":"2309_CR28","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"2309_CR29","doi-asserted-by":"publisher","unstructured":"Broad Institute TCGA Genome Data Analysis Center. Analysis-ready standardized TCGA data from Broad GDAC Firehose 2016_01_28 run. Broad Institute of MIT and Harvard (2016). https:\/\/doi.org\/10.7908\/C11G0KM9.","DOI":"10.7908\/C11G0KM9"},{"key":"2309_CR30","unstructured":"GDC Data Portal. Available at: https:\/\/portal.gdc.cancer.gov\/. (Accessed 25 Oct 2018)."},{"key":"2309_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109\u20131112 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2309_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/cdd.2013.106","volume":"20","author":"E Passante","year":"2013","unstructured":"Passante, E., W\u00fcrstle, M. L., Hellwig, C. T., Leverkus, M. & Rehm, M. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ. 20, 1521\u20131531 (2013).","journal-title":"Cell Death Differ."},{"key":"2309_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrm2312","volume":"9","author":"RC Taylor","year":"2008","unstructured":"Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231\u2013241 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2309_CR34","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood.V93.8.2671","volume":"93","author":"LA Hogarth","year":"1999","unstructured":"Hogarth, L. A., Hall, A. G. & Increased, B. A. X. expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 93, 2671\u20132678 (1999).","journal-title":"Blood"},{"key":"2309_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.leu.2402340","volume":"16","author":"T K\u00f6hler","year":"2002","unstructured":"K\u00f6hler, T. et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 16, 22\u201329 (2002).","journal-title":"Leukemia"},{"key":"2309_CR36","first-page":"2860","volume":"5","author":"O Bairey","year":"1999","unstructured":"Bairey, O., Zimra, Y., Shaklai, M., Okon, E. & Rabizadeh, E. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin. Cancer Res. 5, 2860\u20132866 (1999).","journal-title":"Clin. Cancer Res."},{"key":"2309_CR37","first-page":"533","volume":"8","author":"SH Meterissian","year":"2001","unstructured":"Meterissian, S. H. et al. Bcl-2 is a useful prognostic marker in Dukes\u2019 B colon cancer. Ann. Surg. Oncol. 8, 533\u2013537 (2001).","journal-title":"Ann. Surg. Oncol."},{"key":"2309_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molonc.2008.01.004","volume":"2","author":"LM Vargas-Roig","year":"2008","unstructured":"Vargas-Roig, L. M. et al. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol. Oncol. 2, 102\u2013111 (2008).","journal-title":"Mol. Oncol."},{"key":"2309_CR39","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/sj.bjc.6600217","volume":"86","author":"FE McDonald","year":"2002","unstructured":"McDonald, F. E. et al. The prognostic influence of bcl-2 in malignant glioma. Br. J. Cancer 86, 1899\u20131904 (2002).","journal-title":"Br. J. Cancer"},{"key":"2309_CR40","unstructured":"Inada, T., Kikuyama, S., Ichikawa, A., Igarashi, S. & Ogata, Y. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res. 18, 2003\u20132010 (1998)."},{"key":"2309_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JTO.0b013e318199e03a","volume":"4","author":"DJ Renouf","year":"2009","unstructured":"Renouf, D. J. et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J. Thorac. Oncol. 4, 486\u2013491 (2009).","journal-title":"J. Thorac. Oncol."},{"key":"2309_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.20","volume":"6","author":"V Labi","year":"2015","unstructured":"Labi, V. & Erlacher, M. How cell death shapes cancer. Cell Death Dis. 6, e1675 (2015).","journal-title":"Cell Death Dis."},{"key":"2309_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrc.2016.58","volume":"16","author":"G Ichim","year":"2016","unstructured":"Ichim, G. & Tait, S. W. G. A fate worse than death: apoptosis as an oncogenic process. Nat. Rev. Cancer 16, 539\u2013548 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2309_CR44","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1111\/febs.14516","volume":"285","author":"A Hantusch","year":"2018","unstructured":"Hantusch, A., Rehm, M. & Brunner, T. Counting on death \u2013 quantitative aspects of Bcl-2 family regulation. FEBS J. 285, 4124\u20134138 (2018).","journal-title":"FEBS J."},{"key":"2309_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65\u201380 (2018).","journal-title":"Cell Death Differ."},{"key":"2309_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4349-y","volume":"18","author":"X Kong","year":"2018","unstructured":"Kong, X. et al. ZBP-89 and Sp1 contribute to Bak expression in hepatocellular carcinoma cells. BMC Cancer 18, 419 (2018).","journal-title":"BMC Cancer"},{"key":"2309_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-256","volume":"6","author":"A Arellano-Llamas","year":"2006","unstructured":"Arellano-Llamas, A. et al. High Smac\/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer 6, 256 (2006).","journal-title":"BMC Cancer"},{"key":"2309_CR48","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/sj.jid.5700239","volume":"126","author":"M Leverkus","year":"2006","unstructured":"Leverkus, M. & Gollnick, H. \u2018Bak (and Bax) to the future\u2019 - of primary melanoma prognosis? J. Investig. Dermatol. 126, 1212\u20131214 (2006).","journal-title":"J. Investig. Dermatol."},{"key":"2309_CR49","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/sj.bjc.6600789","volume":"88","author":"J Kupryja\u0144czyk","year":"2003","unstructured":"Kupryja\u0144czyk, J. et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEKI expression in 229 ovarian carcinomas treated with platinum-based regimen. Br. J. Cancer 88, 848\u2013854 (2003).","journal-title":"Br. J. Cancer"},{"key":"2309_CR50","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1200\/JCO.2000.18.22.3775","volume":"18","author":"M Baekelandt","year":"2000","unstructured":"Baekelandt, M., Holm, R., Nesland, J. M., Trop\u00e9, C. G. & Kristensen, G. B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J. Clin. Oncol. 18, 3775\u20133781 (2000).","journal-title":"J. Clin. Oncol."},{"key":"2309_CR51","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","volume":"101","author":"G Del Poeta","year":"2003","unstructured":"Del Poeta, G. et al. Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101, 2125\u20132131 (2003).","journal-title":"Blood"},{"key":"2309_CR52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/jjco\/hyn089","volume":"38","author":"SH Jeong","year":"2008","unstructured":"Jeong, S. H. et al. Low expression of bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. Jpn. J. Clin. Oncol. 38, 661\u2013669 (2008).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"2309_CR53","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-06-3063","volume":"13","author":"YK Seok","year":"2007","unstructured":"Seok, Y. K. et al. Low expression of bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin. Cancer Res. 13, 4146\u20134153 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2309_CR54","first-page":"1487","volume":"41","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Bromodomain\u2011containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2\u2011antagonist\/killer protein. Oncol. Rep. 41, 1487\u20131496 (2019).","journal-title":"Oncol. Rep."},{"key":"2309_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138955","volume":"10","author":"Y Luo","year":"2015","unstructured":"Luo, Y. et al. High Bak expression is associated with a favorable prognosis in breast cancer and sensitizes breast cancer cells to paclitaxel. PLoS ONE 10, e0138955 (2015).","journal-title":"PLoS ONE"},{"key":"2309_CR56","first-page":"351","volume":"21","author":"K Endo","year":"2009","unstructured":"Endo, K. et al. Clinical significance of Smac\/DIABLO expression in colorectal cancer. Oncol. Rep. 21, 351\u2013355 (2009).","journal-title":"Oncol. Rep."},{"key":"2309_CR57","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2478\/v10042-10-0061-8","volume":"48","author":"B Dobrzycka","year":"2010","unstructured":"Dobrzycka, B. et al. Prognostic significance of smac\/DIABLO in endometrioid endometrial cancer. Folia Histochem. Cytobiol. 48, 678\u2013681 (2010).","journal-title":"Folia Histochem. Cytobiol."},{"key":"2309_CR58","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ejca.2009.11.023","volume":"46","author":"O Grzybowska-Izydorczyk","year":"2010","unstructured":"Grzybowska-Izydorczyk, O., Cebula, B., Robak, T. & Smolewski, P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur. J. Cancer 46, 800\u2013810 (2010).","journal-title":"Eur. J. Cancer"},{"key":"2309_CR59","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4149\/neo_2011_05_430","volume":"58","author":"P Pluta","year":"2011","unstructured":"Pluta, P. et al. Correlation of Smac\/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 58, 430\u2013435 (2011).","journal-title":"Neoplasma"},{"key":"2309_CR60","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nm.2385","volume":"17","author":"Q Huang","year":"2011","unstructured":"Huang, Q. et al. Caspase 3\u2013mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 17, 860\u2013866 (2011).","journal-title":"Nat. Med."},{"key":"2309_CR61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10555-018-9736-y","volume":"37","author":"R Zhao","year":"2018","unstructured":"Zhao, R. et al. Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. Cancer Metastasis Rev. 37, 227\u2013236 (2018).","journal-title":"Cancer Metastasis Rev."},{"key":"2309_CR62","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/jid.2014.18","volume":"134","author":"AL Donato","year":"2014","unstructured":"Donato, A. L. et al. Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. J. Invest. Dermatol. 134, 1686\u20131692 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"2309_CR63","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2309_CR64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"2309_CR65","first-page":"1865","volume":"4","author":"L Tang","year":"1998","unstructured":"Tang, L. et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin. Cancer Res. 4, 1865\u20131871 (1998).","journal-title":"Clin. Cancer Res."},{"key":"2309_CR66","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/sj.jid.5700192","volume":"126","author":"LF Fecker","year":"2006","unstructured":"Fecker, L. F. et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J. Invest. Dermatol. 126, 1366\u20131371 (2006).","journal-title":"J. Invest. Dermatol."},{"key":"2309_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0560.2006.00700.x","volume":"34","author":"G Tchernev","year":"2007","unstructured":"Tchernev, G. & Orfanos, C. E. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J. Cutan. Pathol. 34, 247\u2013256 (2007).","journal-title":"J. Cutan. Pathol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2309-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:44:53Z","timestamp":1670251493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2309-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2309-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}